Search the Newsreel

Rentokil Initial plc (LON:RTO) Given Consensus Recommendation of "Moderate Buy" by Analysts

Analysts have issued a "Moderate Buy" consensus recommendation for Rentokil Initial plc (LON:RTO), with an average 12-month price target of GBX 463. Despite some brokers lowering their price targets, major firms like Citigroup and Jefferies maintain buy ratings. Shares recently opened down 2.0% near …

Rentokil And Rollins: Revisiting The Quality And Valuation Gap After Earnings (NYSE:RTO)

Rentokil Initial PLC To Go Ex-Dividend On August 14th, 2026 With 0.224 USD Dividend Per Share

Rentokil Initial PLC is scheduled to go ex-dividend on August 14th, 2026. The company will be distributing a dividend of 0.224 USD per share to its shareholders. Investors should note this date for dividend eligibility.

Enterprise value to EBITDA forward of Cytokinetics, Incorporated – NASDAQ:CYTK

This article provides an overview of the "Enterprise value to EBITDA forward" metric for Cytokinetics, Incorporated (NASDAQ: CYTK) as listed on TradingView. It indicates that the data is sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The content mainly consists …

Tokyo Plast International accepts resignation of Company Secretary Sonal Gandhi

Rentokil Initial (LON:RTO) Price Target Lowered to GBX 431 at JPMorgan Chase & Co.

JPMorgan Chase & Co. has lowered its price target for Rentokil Initial (LON:RTO) to GBX 431 from GBX 477, while maintaining an "overweight" rating. This new target suggests a potential upside of approximately 24% from the current share price. Despite the reduction, the company …

Rentokil Initial slips Friday, underperforms market

Shares of Rentokil Initial PLC (RTO) dropped 2.05% to £3.45 on Friday, while the FTSE 100 Index (UKX) also fell 0.27%. The company's stock closed 31.99% below its 52-week high of £5.07, recorded on April 15th. This performance occurred during an overall dismal trading …

Cytokinetics (CYTK) insider schedules 24,000-share option-related stock sale

Cytokinetics insider Andrew Callos has filed a Form 144 to sell 24,000 shares of common stock on July 30, 2026, connected to an exercise of stock options. The filing also details previous Rule 10b5-1 plan sales by Callos in May and June 2026, outlining …

Rentokil Initial (NYSE:RTO) Issues Earnings Results, Misses Estimates By $0.32 EPS

Analysts Had Rentokil Initial 1H Adj Pretax Profit at $442M

Analysts expected Rentokil Initial's first-half adjusted pretax profit to be $442 million. This estimate was based on a Visible Alpha consensus of seven analysts. The reported figure will be closely watched against this expectation.

Rentokil Initial plc (RTO) Stock Forecasts

Japan Earnings Wrap: Tokyo Electron, Mizuho Financial Rise, Nomura Research Slides

The Bull Case For Cytokinetics (CYTK) Could Change Following UK NHS Backing Of Aficamten Access

Cytokinetics recently secured marketing authorization for MYQORZO (aficamten) in the UK to treat obstructive hypertrophic cardiomyopathy, with NICE recommending its use within the NHS. This approval, supported by Phase 3 trial data, is a significant step for the company, reinforcing its investment narrative around …

Andrew Callos of Cytokinetics Inc (CYTK) sells 14,000 shares after exercising options

Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics Inc (CYTK), exercised 14,000 non-qualified stock options at $23.26 per share and subsequently sold all 14,000 shares at $79.88 per share under a Rule 10b5-1 trading plan. After these transactions, he holds 10,000 stock options …

Rentokil Initial PLC (RKLIF) (H1 2026) Earnings Call Highlights: Revenue Growth and Margin ...

This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revenue increased 4.5% to $3,589 million, with organic growth of 3.6%. Operating profit rose 6.6% …

Rentokil Initial (RTO) Looks 18.2% Undervalued on GF Value™

Cash, margins and debt: Rentokil Initial (NYSE: RTO) details H1 2026

Rentokil Initial (NYSE: RTO) reported strong financial results for H1 2026, with group revenue reaching $3,589m, an increase of 6.7%. The company saw its adjusted operating profit rise by 8.8% to $556m, leading to an improved adjusted operating margin of 15.5%. Net debt decreased …

Cytokinetics wins UK approval, NICE backing for heart disease drug

Cytokinetics' drug Myqorzo for obstructive hypertrophic cardiomyopathy (oHCM) has received approval from Britain's medicines regulator and a recommendation for NHS reimbursement from the National Institute for Health and Care Excellence (NICE). This will make the drug accessible to an estimated 6,600 patients in England …

Rentokil Initial plc Stock 12‑Month Price Target Cut to $34.9, Implies 19% Upside

Rentokil Initial plc (RTO) has seen its average 12-month price target reduced to $34.9 from $35.27 by 14 analysts, implying a potential 19% upside from its July 29 closing price. Despite the slight target cut, the consensus rating for the stock remains a "Buy" …

Cytokinetics' cardiomyopathy drug cleared for NHS use

Cytokinetics' cardiac myosin inhibitor Myqorzo has received clearance for NHS use in the UK, making it a competitor to Bristol Myers Squibb's Camzyos. The drug is approved as an add-on treatment for adults with NYHA class II-III obstructive hypertrophic cardiomyopathy (HCM). This approval follows …

MHRA approves Cytokinetics’ aficamten for heart condition in UK

The UK's MHRA has granted marketing authorization for Cytokinetics' drug aficamten (MYQORZO) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. The National Institute for Health and Care Excellence (NICE) also recommended its use in England and Wales. This approval follows positive data …

Earnings call transcript: Rentokil Initial slips on H1 2026 growth worries

Rentokil Initial reported a 4.5% rise in H1 revenue to $3.589 billion and a 6.6% increase in operating profit, driven by strong gains in North America and international pest control. Despite solid financial performance and improved free cash flow, the company's shares dropped significantly …

Cytokinetics Secures MYQORZO Marketing Authorization in the UK

Cytokinetics has been granted marketing authorization for MYQORZO (aficamten) in the UK for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This approval, along with a positive recommendation from NICE, validates the drug's efficacy demonstrated in the SEQUOIA-HCM trial. While common adverse reactions include hypertension, palpitations, …

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

Cytokinetics announced that the MHRA has granted marketing authorization for MYQORZO® (aficamten) across the UK for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in eligible adult patients. Simultaneously, NICE issued guidance recommending aficamten for use in eligible adult patients in England and Wales. …

OMERS ADMINISTRATION Corp Invests $1.35 Million in Stoke Therapeutics, Inc. $STOK

OMERS ADMINISTRATION Corp initiated a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the first quarter, purchasing 41,500 shares valued at approximately $1.35 million. Other institutional investors like Baillie Gifford & Co., Hussman Strategic Advisors Inc., and Candriam S.C.A. also hold significant stakes, with …

Rentokil Initial Shares Plummet 17% as North America Weakness Overshadows H1 Profit

Rentokil Initial's shares plunged by 17% despite solid first-half results, as investors were rattled by weaknesses in its North American business, particularly in residential lead flow and commercial revenue growth. The company scrapped its 2027 North America margin target to prioritize volume and reinvestment …

Cytokinetics (CYTK) Expected to Release Earnings on Thursday

Wall Street expects a year-over-year decline in earnings on lower revenues when Cytokinetics (CYTK) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …

British Shares Fall as Central Bank Holds Rate; Rentokil Initial Plunges

Rentokil Initial (NYSE:RTO) Shares Gap Down Following Weak Earnings

Rentokil Initial plc 2026 Q2 - Results - Earnings Call Presentation (NYSE:RTO) 2026-07-30

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Rentokil: What We Think of the Stock After Earnings

Stoke Therapeutics Inc (STOK) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Stoke Therapeutics Inc (STOK), indicating its current valuation score is 8.30, ranking 147 out of 384 in the Biotechnology & Medical Research industry. The company's P/E ratio is -10.31, significantly below its recent high and above its …

PT Goto Gojek Tokopedia Tbk (GTOFF) Q2 2026 Earnings Call Highlights: Strong User Growth and ...

This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points PT Goto Gojek Tokopedia Tbk (GTOFF) reported a net income of Rs 252 billion in …

Stoke Therapeutics (STOK) Expected to Release Earnings on Monday

Stoke Therapeutics (NASDAQ:STOK) is anticipated to release its Q2 2026 earnings before market open on Monday, August 3rd. Analysts project a loss of $0.82 per share and $4.89 million in revenue. The company's stock, currently trading around $29.20, holds a "Moderate Buy" consensus rating …

Stoke Therapeutics, Inc. $STOK Position Increased by Redmile Group LLC

Redmile Group LLC increased its stake in Stoke Therapeutics (STOK) by 3.2% in the first quarter, now owning 4.16 million shares valued at $135.6 million. Other institutional investors like Janus Henderson and State Street also boosted their positions, while company insiders sold shares. Despite …